For over two years, the biopharmaceutical industry has revolved around rapid development, manufacture, and rollout of vaccines in response to the COVID-19 pandemic. Now as the world reverts to some sense of normality, demand has plummeted for the likes of J&J’s viral vector vaccine and Moderna’s messenger RNA (mRNA) vaccine, resulting in the lowering of financial forecasts, ending of manufacturing contracts, and freeing of production capacity.

But where do vaccines — the great pharmaceutical success story of the past few years — go from here? VBI Vaccines discussed the future of vaccines and the growing opportunity of immunotherapeutics at the September 2022 BioProcess International Conference and Exhibition (part of Biotech Week Boston) in a fireside chat led by BioProcess Insider. VBI executives highlighted that the future is bright considering the advent and validation of mRNA, a newly robust financing environment, and a new focus on therapeutic vaccines.

This eBook summarizes key insights from that fireside discussion, bringing supporting information from the most relevant vaccine-related news from the past few months of BioProcess Insider. Read on to learn about the biopharmaceutical industry’s increasing attention to development of not only prophylactic, but also therapeutic vaccines.

Fill out the form below to read the complete eBook now.